Search Result

Results for "

α7 nAChR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	nAChR (76) 5-HT Receptor (9) Antibiotic (2) AP-1 (1) Apoptosis (3) Autophagy (2) Bacterial (4) Cholinesterase (ChE) (2) Dengue virus (2) Flavivirus (2) HIV (2) HSV (2) Isotope-Labeled Compounds (3) JAK (2) Mitophagy (2) mTOR (1) NF-κB (1) NO Synthase (1) Nuclear Factor of activated T Cells (NFAT) (1) p38 MAPK (1) Parasite (4) Potassium Channel (2) SARS-CoV (2) STAT (1)
By Research Areas:	Cancer (7) Infection (4) Inflammation/Immunology (9) Metabolic Disease (2) Neurological Disease (71)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: nAChR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146066

*α7 nAchR-JAK2-STAT3 agonist 1*	nAChR JAK STAT NO Synthase	Inflammation/Immunology
α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-146066A

*(R)-α7 nAchR-JAK2-STAT3 agonist 1*	Others	Others
(R)-α7 nAchR-JAK2-STAT3 agonist 1 is the R-enantiomer of α7 nAchR-JAK2-STAT3 agonist 1 (HY-146066). α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-110087

4BP-TQS	nAChR	Neurological Disease
4BP-TQS is a potent allosteric agonist of α7 *nAChR. 4BP-TQS activates nAChRs* via an allosteric transmembrane site .

HY-12150

CCMI 1 Publications Verification AVL-3288; UCI-4083	nAChR	Neurological Disease
CCMI (AVL-3288) is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs. CCMI has potential in CNS diseases with cognitive dysfunction .

HY-12151

NS 1738 NSC 213859	nAChR	Neurological Disease
NS 1738 (NSC 213859) is a novel positive allosteric modulator of the α7 nAChR, with respect to positive modulation of α7 nAChR (EC₅₀=3.4 μM in oocyte experiments).

HY-160529

*α7 nAChR* Modulator-2**	nAChR	Neurological Disease
α7 nAChR Modulator-2 (Compound 7b) is a α7 nAChR positive allosteric modulator (PAM) with an *EC₅₀ of 2.1 μM. α7 nAChR* Modulator-2 can be used for the research of cognitive disorders .**

HY-157958

*α7 nAChR* Modulator-3**	nAChR	Neurological Disease
α7 nAChR modulator-3 (Compound 6p) is a α7 nAChR positive allosteric Modulator with a IC₅₀ value of 1.3 μM. α7 nAChR Modulator-3 can be used to inhibit auditory gating defects in a mouse schizophrenic model .

HY-146405

nAChR antagonist 1	nAChR	Neurological Disease Inflammation/Immunology
nAChR antagonist 1 (compound B15) is an excellent α7 nAChR antagonist with an IC₅₀ value of 3.3 μM. nAChR antagonist 1 can be used for researching schizophrenia, Alzheimer’s disease and inflammatory disorders .

HY-107683

LY-2087101	nAChR	Neurological Disease
LY-2087101 is an allosteric potentiator of α7 nAChRs. LY-2087101 causes potentiation of agonist-evoked α7 responses by binding within the nAChR transmembrane region .

HY-105670A

PHA-543613 hydrochloride	nAChR	Neurological Disease
PHA-543613 hydrochloride is an oral or active α7 nAChR agonist with brain permeability, For α3β4, α1β1γδ, α4β2 and 5-HT3 receptors selective. PHA-543613 hydrochloride affects sensory gating and memory in an in vivo model of schizophrenia .

HY-128575

BNC375	nAChR	Neurological Disease
BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC₅₀ of 1.9 μM. BNC375 exhibits good CNS-agent like properties and clinical candidate potential. .

HY-133011

nAChR agonist 1	nAChR	Neurological Disease
nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC₅₀ of 0.32 µM in a Ca ²⁺ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease .

HY-18060

Bradanicline TC-5619	nAChR	Neurological Disease
Bradanicline is a highly selective α7 nicotinic acetylcholine receptor (nAChR) agonist (humanα7 nAChR: EC₅₀=17 nM; K_i= 1.4 nM). Bradanicline is used for the research of cognitive disorders .

HY-135483A

AR-R17779 hydrochloride	nAChR	Neurological Disease
AR-R17779 hydrochloride is a potent and selective full agonist of *nAChR, with K_is of 92 and 16000 nM for α7 and α4β2* subtype, respectively. AR-R17779 hydrochloride can improve learning and memory in rats. AR-R17779 hydrochloride also has anxiolytic activity. AR-R17779 hydrochloride can reduce inflammation by activating antiinflammatory cholinergic (vagal) pathways .

HY-19490

VQW-765 AQW-051	nAChR	Neurological Disease
VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pK_D value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety .

HY-19411

SSR180711 hydrochloride	nAChR	Neurological Disease
SSR180711 hydrochloride is an orally active, selective and reversible α7 acetylcholine nicotinic receptor (n-AChRs) partial agonist. SSR180711 hydrochloride can act on rat α7 n-AChR (K_i=22 nM; IC₅₀=30 nM) and human α7 n-AChR (K_i=14 nM; IC₅₀=18 nM). SSR180711 hydrochloride increases glutamatergic neurotransmission, ACh release and long-term potentiation (LTP) in the hippocampus .

HY-12560D

PNU-282987 S enantiomer free base	nAChR	Others
PNU-282987 S enantiomer free base is the S-enantiomer of PNU-282987 free base. PNU-282987 is an α7 nicotinic acetylcholine receptor (α7 nAChR) agonist.

HY-59201A

A-582941 dihydrochloride	nAChR 5-HT Receptor	Neurological Disease
A-582941 dihydrochloride is a potent, selective and brain-penetrant partial agonist of α7 nAChR, with K_is of 10.8 and 16.7 nM in rat brain membranes and human frontal cortex, respectively. A-582941 dihydrochloride also binds to human 5-HT₃ receptor with a K_i of 150 nM. A-582941 has the potential for cognitive deficits associated with various neurodegenerative and psychiatric disorders research .

HY-18060A

Bradanicline hydrochloride TC-5619 hydrochloride	nAChR	Neurological Disease
Bradanicline hydrochloride (TC-5619 hydrochloride) is the hydrochloride salt form of Bradanicline (HY-18060). Bradanicline hydrochloride is a selective agonist for α7 nicotinic acetylcholine receptor (nAChR), with EC₅₀ of 17 nM for human α7 nAChR and K_i of 1.4 nM. Bradanicline hydrochloride is used for the research of cognitive disorders and schizophrenia .

HY-107672

MG624 Stilonium iodide	nAChR	Neurological Disease
MG624 is a potent and selective neuronal α7 nAChR antagonist with a K_i of 106 nM .

HY-107673

RJR-2429 dihydrochloride	nAChR	Neurological Disease
RJR 2429 hydrochloride is a α4β2 and α7 nAChR agonist .

HY-146404

T761-0184	nAChR	Neurological Disease
T761-0184 is a potent α7 nicotinic receptor (nAChR) antagonist .

HY-N2332A

Methyllycaconitine citrate Maximum Cited Publications 26 Publications Verification MLA	nAChR	Neurological Disease
Methyllycaconitine citrate is a specific antagonist of α7 neuronal nicotinic acetylcholine receptor (α7nAChR) with blood-brain barrier permeability.

HY-15430A

Encenicline hydrochloride 5 Publications Verification EVP-6124 hydrochloride	nAChR	Neurological Disease
Encenicline hydrochloride (EVP-6124 hydrochloride) is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs).

HY-15430

Encenicline EVP-6124	nAChR	Neurological Disease
Encenicline (EVP-6124) is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs).

HY-16748

Nelonicline ABT-126	nAChR	Neurological Disease
Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (K_i=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease .

HY-117611

GAT107	nAChR	Neurological Disease
GAT107 (compound 1b) is a potent α7 nAChR ago-PAMs (positive allosteric modulators) .

HY-16748A

Nelonicline citrate ABT-126 citrate	nAChR	Neurological Disease
Nelonicline (ABT-126) citrate is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (K_i=12.3 nM). Nelonicline citrate is used for the research of shizophrenia and Alzheimer's disease .

HY-18039

WAY-361789 SEN15924	Cholinesterase (ChE)	Neurological Disease
WAY-361789 (SEN15924) is an orally active agonist for α7 nicotinic acetylcholine receptor (α7 *nAChR) with an EC₅₀* of 0.18 μM. WAY-361789 improves the cognitive function, exhibits potential in ameliorating Alzheimer’s Disease and schizophrenia .

HY-148325

α7 Nicotinic receptor agonist-1	nAChR	Neurological Disease
α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .

HY-129674

PHA 568487 free base	nAChR	Neurological Disease
PHA 568487 free base is a selective alpha 7 nicotinic acetylcholine receptor (α-7 *nAchR*) agonist. PHA 568487 free base reduces neuroinflammation .

HY-107682

TQS	nAChR	Neurological Disease Inflammation/Immunology
TQS is a α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain .

HY-105670

PHA-543613	nAChR	Neurological Disease
PHA-543613 is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a K_i of 8.8 nM. PHA-543613 displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors . PHA-543613 can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research .

HY-105670B

PHA-543613 dihydrochloride	nAChR	Neurological Disease
PHA-543613 dihydrochloride is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a K_i value of 8.8 nM. PHA-543613 dihydrochloride displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors . PHA-543613 dihydrochloride can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research .

HY-P1264

α-Bungarotoxin 5 Publications Verification	nAChR	Neurological Disease
α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs). α-Bungarotoxin, a selective α7 receptor blocker, blocks α7 currents with an IC₅₀ of 1.6 nM and has no effects on α3β4 currents at concentrations up to 3 μM .

HY-108057

Facinicline RG3487 free base	nAChR 5-HT Receptor	Neurological Disease
Facinicline (RG3487) is an orally active nicotinic α7 receptor partial agonist, with a K_i of 6 nM for α7 human nAChR. Facinicline improves cognition and sensorimotor gating in rodents. Facinicline hydrochloride shows high affinity (antagonist) to 5-HT₃Rs with a K_i value of 1.2 nM .

HY-114269

(-)-(S)-B-973B	nAChR	Neurological Disease
(-)-(S)-B-973B is a potent allosteric agonist and positive allosteric modulator of α7 nAChR, with antinociceptive activity .

HY-11053

S 24795	nAChR	Neurological Disease
S 24795 is a partial agonist of α7 nAChR and improves mnemonic function in aged mice for the research of aging-related memory disturbances .

HY-107678

SEN12333 WAY-317538	nAChR	Neurological Disease
SEN 12333 (WAY-317538) is a potent, selective and orally active α7 nAChR agonist. SEN12333 displays high affinity for the rat α7 nAChRs expressed in GH4C1 cells (K_>i=260 nM) and acts as full agonist in functional Ca ²⁺ flux studies (EC₅₀=1.6 μM). SEN 12333 is used for AD and schizophrenia research .

HY-10814

CP-810123	nAChR	Neurological Disease
CP-810123 is a brain-permeable agonist of α7 nAChR for the research of cognitive impairment associated with psychiatric or neurological disorders such as schizophrenia and Alzheimer's disease .

HY-108057A

Facinicline hydrochloride RG3487 hydrochloride	nAChR 5-HT Receptor	Neurological Disease
Facinicline hydrochloride (RG3487 hydrochloride) is an orally active nicotinic α7 receptor partial agonist, with a K_i of 6 nM for α7 human nAChR. Facinicline hydrochloride (RG3487 hydrochloride) improves cognition and sensorimotor gating in rodents. Facinicline hydrochloride (RG3487 hydrochloride) shows high affinity (antagonist) to 5-HT₃Rs with a K_i value of 1.2 nM .

HY-107666

PHA 568487	nAChR	Neurological Disease Inflammation/Immunology
PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 *nAchR*) .PHA 568487 reduces neuroinflammation and oxidative stress . PHA-568487 has rapid brain penetration .

HY-P5823

Azemiopsin	nAChR	Neurological Disease
Azemiopsin is a potent nicotinic acetylcholine receptor (nAChR) inhibitor with IC₅₀s of 0.18 μM and 22 μM against T. californica nAChR and human α7 nAChR, respectively. Azemiopsin blocks acetylcholine-induced currents in Xenopus oocytes heterologously expressing human muscle-type nAChR .

HY-107671

DMAB-anabaseine dihydrochloride	nAChR	Neurological Disease
DMAB-anabaseine dihydrochloride is a selective nicotinic α7 receptor partial agonist and an α4β2 nAChR antagonist. DMAB-anabaseine dihydrochloride shows cognition-enhancing effects .

HY-120609

BMS-902483	nAChR	Neurological Disease
BMS-902483 is a quinuclidine-containing spirooxazolidine that is a partial agonist of the α7 nicotinic acetylcholine receptor (nAChR). BMS-902483 improves cognitive ability in preclinical rodent models. .

HY-B0072

Tropisetron 4 Publications Verification SDZ-ICS-930 free base	5-HT Receptor nAChR p38 MAPK NF-κB AP-1 Nuclear Factor of activated T Cells (NFAT) JAK	Neurological Disease Inflammation/Immunology Cancer
Tropisetron (SDZ-ICS-930 free base) is an orally active anti-inflammatory and antiemetic agent. Tropisetron is 5-HT₃R antagonists with a K_i of 5.3 nM. Tropisetron is also a partial agonist of α7 nicotinic receptor (α7 *nAChR) with an EC₅₀* of 1.3 μM. In addition, Tropisetron has antitumor and neuroprotective effects .

HY-B1178A

R-(+)-Cotinine (+)-Cotinine; (R)-Cotinine; (R)-NIH-10498	nAChR	Neurological Disease
R-(+)-Cotinine ((+)-Cotinine), a Nicotine metabolite, lacks significant activity across a wide range of pharmacological targets. R-(+)-Cotinine can enhance the Ach-evoked current in human α7 nAChRs .

HY-114791

Lobelanidine	nAChR	Neurological Disease
Lobelanidine is an antagonist for nicotinic acetylcholine receptor (nAChR), which inhibits α7 nAChR response and α3β2/α3β4 nAChR responses, with IC₅₀ of 2.8 and 8.2 μM .

HY-116507

AZD0328	nAChR	Neurological Disease
AZD0328 is a selective α7 nAChR partial agonist. AZD0328 selectively enhances midbrain dopaminergic neuronal activity and enhances cortical dopamine levels in rats. AZD0328 improves cognitive performance .

HY-105858

BNC210 H-Ile-Trp-OH; IW-2143	nAChR	Neurological Disease
BNC210 (H-Ile-Trp-OH) is an orally active α7 nAChR negative alteration modulator (NAM) with no apparent side effects. BNC210 exhibits acute anxiolytic activity in rodent models of anxiety. BNC210 inhibits rat and human α7 nAChR currents (in stably transfected cell lines) induced by acetylcholine, nicotine, choline, and the a7-specific agonist PNU-282987 with IC₅₀ values in the range of 1.2 to 3 μM. BNC210 can be used in studies of anxiety, trauma, and stressor-related disorders .

Cat. No.	Product Name	Target	Research Area

HY-P1264

α-Bungarotoxin 5 Publications Verification	nAChR	Neurological Disease
α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs). α-Bungarotoxin, a selective α7 receptor blocker, blocks α7 currents with an IC₅₀ of 1.6 nM and has no effects on α3β4 currents at concentrations up to 3 μM .

HY-P5823

Azemiopsin	nAChR	Neurological Disease
Azemiopsin is a potent nicotinic acetylcholine receptor (nAChR) inhibitor with IC₅₀s of 0.18 μM and 22 μM against T. californica nAChR and human α7 nAChR, respectively. Azemiopsin blocks acetylcholine-induced currents in Xenopus oocytes heterologously expressing human muscle-type nAChR .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0175

Cytisinicline 1 Publications Verification Cytisine; Sophorine; Baptitoxine	Alkaloids Structural Classification Classification of Application Fields Leguminosae Source classification Pyridine Alkaloids Metabolic Disease Plants Thermopsis lanceolala R.Br. Disease Research Fields	nAChR
Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-15310

Ivermectin 20+ Cited Publications MK-933; CD-5024; K-237	Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Antiviral Anti-parasitic Disease Research Disease Research Fields Cancer	Flavivirus Dengue virus Parasite HIV Mitophagy HSV SARS-CoV Antibiotic Autophagy Bacterial
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .

HY-114791

Lobelanidine	Structural Classification Alkaloids Lobelia tupa L. Other Alkaloids Source classification Campanulaceae Plants	nAChR
Lobelanidine is an antagonist for nicotinic acetylcholine receptor (nAChR), which inhibits α7 nAChR response and α3β2/α3β4 nAChR responses, with IC₅₀ of 2.8 and 8.2 μM .

HY-N0175R

Cytisinicline (Standard)	Alkaloids Structural Classification Leguminosae Source classification Pyridine Alkaloids Plants Thermopsis lanceolala R.Br.	nAChR
Cytisinicline (Standard) is the analytical standard of Cytisinicline. This product is intended for research and analytical applications. Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-15310R

Ivermectin (Standard)	Structural Classification Microorganisms Macrolide Antibiotics Antibiotics Source classification Antiviral Anti-parasitic Disease Research	Dengue virus Flavivirus Parasite HIV Mitophagy HSV SARS-CoV Antibiotic Autophagy Bacterial
Ivermectin (Standard) is the analytical standard of Ivermectin. This product is intended for research and analytical applications. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .

Cat. No.	Product Name	Chemical Structure

HY-106901AS

Asoxime-d4 dichloride
Asoxime-d₄ (dichloride) is the deuterium labeled Asoxime dichloride. Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system[1].

HY-10019S

Varenicline-d4

Varenicline-d₄ is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively[1]. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment[2].

HY-10019AS1

Varenicline-d4 hydrochloride

Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83668

	CHRNA7 Antibody 7nAChR,CHRFAM7A,CHRNA7 (cholinergic receptor; nicotinic; alpha 7; exons 5-10) and FAM7A (family with sequence similarity 7A; exons A-E) fusion; D-10; CHRNA7; CHRNA7-DR1	IHC-P, FC, ELISA	Human

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks